Datapoint: FDA Grants Tentative Nod to Xyrem Rival

The FDA last week granted tentative approval to Avadel Pharmaceuticals’ narcolepsy drug Lumryz, a potential rival to Jazz Pharmaceuticals’ Xyrem, pending the resolution of a patent dispute between the two companies. Lumryz’s main advantage over Xyrem is its extended-release formula, whereas Xyrem requires two nightly doses. For the treatment of narcolepsy, Xyrem currently holds covered or better status for 96% of all insured lives in the U.S. under the pharmacy benefit. About 20% of insured lives have preferred access to Xyrem, largely with utilization management restrictions applied.

Source: MMIT Analytics, as of 7/27/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 17

Datapoint: Humana Inks Deal to Acquire Inclusa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 16

Datapoint: Mississippi Unveils Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 15

Datapoint: SCAN Plots MA Expansion Into Texas

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today